首页> 外国专利> Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

机译:基于结构的肽抑制剂,其靶向Tau VQiink原纤化段

摘要

Aggregated Tau protein is associated with over 20 neurological disorders including Alzheimer's disease. Previous work has shown that Tau's sequence segments VQIINK (SEQ ID NO: 11) and VQIVYK (SEQ ID NO: 9) drive its aggregation, and that inhibitors based on the structure of the VQIVYK (SEQ ID NO: 9) segment partially inhibit Tau aggregation. Here we show that the VQIINK (SEQ ID NO: 11) segment is the more powerful driver of Tau aggregation. Two structures of this segment determined by the cryo EM method MicroED explain its more powerful seeding. Of practical significance, the understanding of the structures has led to the design of structure based peptide inhibitors that effectively inhibit Tau aggregation as well as the ability of exogenous Tau fibrils to seed intracellular Tau in mammalian cells into amyloid.
机译:聚集的Tau蛋白与超过20种神经系统疾病有关,包括阿尔茨海默病。以前的工作表明,Tau的序列段VQiink(SEQ ID NO:11)和VQivyk(SEQ ID NO:9)驱动其聚合,以及基于VQivyk的结构(SEQ ID NO:9)段部分抑制TAU的抑制器聚合。在这里,我们显示VQiink(SEQ ID NO:11)段是TAU聚合的更强大的驱动程序。由Cryo EM方法测定的这段细分的两个结构,微型解释其更强大的播种。实际意义,对结构的理解导致了基于结构的肽抑制剂,有效抑制Tau聚集以及外源性Tau原纤维在哺乳动物细胞中籽粒细胞内Tau的能力进入淀粉样蛋白。

著录项

  • 公开/公告号US10934332B2

    专利类型

  • 公开/公告日2021-03-02

    原文格式PDF

  • 申请/专利权人 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;

    申请/专利号US201816489294

  • 申请日2018-03-15

  • 分类号C07K7;C07K14;C07K5;C07K4;A61K38;A61K49;C07K14/475;C07K14/48;C07K14/47;A61K38/17;A61K38/18;A61K38/19;A61K38/20;A61K38/21;A61P25/28;A61K38/08;A61K38/10;C07K14/435;C07K7/06;C12N9/64;C07K7/08;A61P25;A61P25/02;G01N33/68;A61K51/08;A61K38/16;A61K47/64;A61K39;

  • 国家 US

  • 入库时间 2022-08-24 17:26:34

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号